Compared with placebo , setipiprant significantly reduced the allergen-induced late asthmatic response ( LAR ) , inhibiting the area under the response vs. time curve ( AUC ( 3-10 h ) ) by on average 25.6 % ( P = 0.006 ) and significantly protected against the allergen-induced airway hyperresponsiveness ( AHR ) to methacholine ( P = 0.0029 ) .